The Native Antigen Company Introduces Novel Coronavirus Antigens
Complete the form below to unlock access to ALL audio articles.
The Native Antigen Company has announced the commercial introduction of its Novel Coronavirus antigens, derived from the emerging Wuhan strain. These recombinant proteins are designed to offer scientists high-quality reagents to support ongoing infectious disease research, and the development of diagnostics and vaccines.
The Native Antigen Company has developed rapid response manufacturing capabilities to produce reagents for emerging epidemic diseases according to the World Health Organisation's R&D Blueprint, which urges the accelerated development of vaccines and the increased availability of accurate and reliable diagnostics for priority emerging infectious diseases. These antigens have been derived specifically from the newly identified Novel Coronavirus (2019-nCoV) using The Native Antigen Company’s proprietary mammalian, VirtuE expression system. This system is able to introduce proper protein folding and post-translational modifications to recombinant proteins, which are essential for full biological and antigenic activity.
